anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The literature on nephron-sparing surgery (NSS) in children with bilateral Wilms' tumors (BWT) involving the collection system is mostly comprised of case reports. The present study aimed to summarize the clinical characteristics, treatments, and prognosis of children with BWT involving the collecting system admitted to our pediatric surgery center compared with those whose tumors did not involve the collecting system. A secondary aim was to discuss how to preserve more kidney parenchyma and prevent long-term renal failure under the premise of preventing tumor recurrence.
METHODS: Patients with BWT admitted to our pediatric surgery center between January 2008 and June 2022 were reviewed. All included patients were grouped according to the relationship between the tumor and collecting system according to the intraoperative findings. Group I included children with tumor infiltrating the collecting system, group II included children with tumor growing into the collecting system, and group III included children whose tumor did not involve the collecting system. The clinical features, treatments and prognosis of the patients were analyzed.
RESULTS: Seventy patients were enrolled, including 20 patients with 25 sides of tumors infiltrating the collecting system in group I,10 patients with 13 sides of tumors growing into the collecting system in group II, and 40 patients in group III. There was no significant difference in patients age and gender between group I and group II. In total, 20 patients in group I and 9 patients in group II had partial response (PR) after neoadjuvant chemotherapy. In group I, 22 of 25 sides of tumors underwent NSS; in group II, 11 of 13 sides of tumors underwent NSS. During an average follow-up of 47 months, in group I, 6/20 patients relapsed and 2/20 patients died; in group II, 3/10 patients relapsed and 1/10 patient died. There was no significant difference in 4-year overall survival (OS) rate among groups I, II and III (86.36% vs. 85.71%vs. 91.40%, P = 0.902).
CONCLUSIONS: To preserve renal parenchyma, NSS is feasible for children with BWT involving the collecting system. There was no significant difference in postoperative long-term OS between patients with BWT involving the collecting system and not involving the collecting system.
Abdominal distension is a clinical occurrence that involves a measurable, objective increase in abdominal circumference, which patients report as feeling like pregnant or like having a balloon inside the abdomen. This sign is often preceded by a subjective feeling of abdominal heaviness or bloating, reported as the sensation of having a huge amount of gas trapped inside. These manifestations are highly prevalent and may reflect on their own a gut-brain axis condition, such as functional abdominal distension, or be part of other disorders such as functional dyspepsia or irritable bowel syndrome (IBS). The prevalence of abdominal distension and bloating is 3.5 %. However, when associated with other gut-brain axis disorders such as dyspepsia or IBS, prevalence grows above 50 %. The etiology and pathophysiology of abdominal bloating and distension are highly complex and represent a challenge for both the practitioner and the patient. The patient often associates these sensations with trapped gas, and attributes them to some food intolerance, hence he/she adopts a highly restrictive diet that fails to resolve distension while incurring the risk of nutritional deficiencies or secondary dysbiosis, making a directed treatment guideline necessary.
The invention provides a compound and application thereof in preparing an ATM kinase inhibitor, and belongs to the field of chemical medicines. The structure of the compound is shown as a formula I. The compound provided by the invention can effectively inhibit the activity of ATM kinase, and can be used for preparing an ATM kinase inhibitor and preparing a medicament for preventing and/or treating diseases related to the activity of ATM kinase. In the artATM kinase inhibitors are well known to those skilled in the art as radiosensitizers or chemosensitizers for the treatment of a variety of tumors. The invention also proves that the compound 37 has remarkable radiosensitization effect in inhibiting colorectal cancer cell proliferation, and the radiosensitization effect is better than that of a positive control compound AZD0156. The compound provided by the invention can be used for preparing a radiotherapy or chemotherapy sensitizer, and has a wide application prospect in the radiotherapy and chemotherapy synergistic sensitization treatment of tumors.
The present invention relates to regulation of adult lifespan in eukaryotes.  More particularly, the present invention is directed to methods of assaying for genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. For example, the present invention is directed to genes encoding components of the mitochondrial respiratory chain and genes encoding glycolysis enzymes, which are involved in lifespan regulation, and genes and gene products in pathways controlled by such genes. Other genes and gene products identified as regulating aging and aging pathways include a gene encoding a GTPase; a transcriptional activator; novel genes: llw-1, llw-2, llw-3, and llw-4; genes encoding cytochrome P450 proteins (involved in steroid biosynthesis); a melatonin synthesis gene; genes encoding insulin and insulin-like peptides;  genes encoding heat shock factors; genes encoding catalases; stress-response genes; and metabolic genes. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, antisense nucleic acids, and ribozymes, that regulate, e.g., enhance, adult lifespan via modulation of aging associated proteins; as well as to the use of expression profiles, markers, and compositions in diagnosis and therapy related to lifespan extension, life expectancy, and aging. The present invention also relates to gene therapy involving lifespan associated genes.
The invention provides a technique for extracting immunologic active material from a Shengmu Milk Peptide capsule and a method for making the capsule. The technique of the invention is characterized in that: the raw material colostrum is gathered, screened and preliminarily sterilized, and then is separated by centrifugal cream, degreased, sterilized by pasteurization, separated from casein, processed through ultra-filtration and reverse osmosis, dried by spraying at low temperature, and aseptically packaged until forming base; the Shengmu Milk Peptide capsule contains a plurality of immunoglobulin cytokines. The method is characterized in that: the raw material formulation and weight proportion are embodied in each standard capsule; weighing 50mg to 150mg of colostrum, 50mg to 150mg of additive which is made up of macroergic nutriment, soluble powder, taurine and amylose. The technique comprises the following steps of: blending by the above formula and weight proportion, crashing the ingredients and mixing the ingredients uniformly after 150 to 180 days; then packaging the capsules, checking the filling amount, bottling, labeling, and casing. The invention is simple in technics and convenient for operation. The capsule is suitable for people of low immunity, middle-aged or elder people who are advanced in age and poor in health, sub-health people, overachievers, tumor patients who are recuperated before and after chemotherapy, asthmatic patients, people with liver complaints or other chronic diseases, ladies and the like.
In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
Pancreatic carcinoma (PC) is the deadliest malignant tumors worldwide. Surgical resection is one of the most effective methods for the treatment of PC, but the resectable rate is less than 20% among the patients with PCs, and the recurrent and metastatic rate is more than 80% in two years after resection. Furthermore, it is difficult to achieve tumoral complete responses by traditional therapies including chemotherapy, radiotherapy and transarterial embolization. Ablation has been confirmed one of the most effective methods for solid tumors by recent twenty years and proven to be a radical treatment similar to the surgical resection for the clinical applications of hepatic and renal tumors at early clinical staging in the internationally guidelines. However, the published clinical practices on the thermal ablation of PCs with large-scale cases are rare. One of the most important reasons for this originates from the extreme complexity and difficult regulation of the temperature distribution in tumors during thermal ablation because of the own characteristics of PCs, including highly invasive growth without tumoral capsules, high proportion of the interstitial fiber tissue, and the unusual blood perfusion because of extremely chaotic microvascular structures. The purpose is to explore the efficacy and safety of microwave ablation in the treatment of pancreatic cancer in combination with systematic therapy.
<P>PROBLEM TO BE SOLVED: To provide a vector composed of magnetic particles carrying a cationic polymer and a nucleic acid-containing complex using the vector and to provide a method for forming the complex.  <P>SOLUTION: The vector is composed of magnetic particles carrying out the cationic polymer. The magnetic particles are preferably composed of Fe<SB>3</SB>O<SB>4</SB>. The magnetic particles are preferably nanoparticles having ≤20 nm particle diameter and can be gathered into a specific part in vivo by magnetic force. The carried amount of the cationic polymer is about 1-100 molecules based on one particle of magnetic particles.  <P>COPYRIGHT: (C)2004,JPO
Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
PURPOSE:To provide a cosmetic base composed of a specific peptide-modified silicone derivative, having the characteristics of silicone oil as well as those of polypeptide, free from the defects caused by the combined use of both components and enabling full exhibition of the characteristics. CONSTITUTION:The objective cosmetic base is composed of a compound of formula I (R1 is 1-3C alkyl or phenyl; R2 is side chain of amino acid; R3 is H or 1-20C hydrocarbon group; R4 is H or OH; A is ethylene or propylene; B is 1-3C alkylene; (l) is 0-200: (m) is 0-20; (n) is 1-50). The cosmetic compounded with said compound imparts gloss and moistness to the hair, improves the combing smoothness, prevents the generation of split hair, imparts gloss and moistness also to the skin and gives smooth skin. The emulsified state is stably maintained even after the storage over a long period. The compound of formula I can be produced e.g. by reacting an epoxy-modified silicone derivative of formula II with a peptide of formula III.
The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and/or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.
There is provided a computer-implemented method for generating an optimised intervention interval for a subject. Data associated with the subject is acquired (202). A predicted intervention interval of the subject is estimated (204) based on the data and an intervention regression model. For each predetermined intervention interval, a clinical event coverage value and/or an interval error value is estimated (206) based on the data and a risk prediction model. An intervention interval is indicative of a frequency at which an intervention is provided to the subject. A clinical event coverage value is indicative of a likelihood of preventing /alleviating a future clinical event. An interval error value is indicative of a delay between the predicted and the respective predetermined intervention interval. An optimisation criterion associated with the clinical event coverage value and/or the interval error value is acquired. A intervention interval for which the optimisation criterion is satisfied is selected.
BACKGROUND: The impact of extended steroid administration on patients with autoimmune pancreatitis after a 3-year maintenance period remains poorly understood. This study analyzed the advantage and disadvantage of continuing steroid therapy beyond 3 years.
METHODS: In this retrospective multicenter study across 17 institutions, patients who successfully completed 3 years of maintenance therapy without experiencing relapse were categorized into two groups: the maintenance therapy discontinuation group, who discontinued steroid therapy after the initial 3-year period, and maintenance therapy continuation group, who continued steroid therapy beyond 3 years. The cumulative relapse rate after 3 years of maintenance therapy was the primary outcome. Relapse predictors were compared using the Gray test for cumulative relapse incidence by specific factor.
RESULTS: Of 211 patients, 105 experienced no relapse during the 3-year maintenance therapy and were divided into two groups: 69 in the maintenance therapy discontinuation group and 36 in the maintenance therapy continuation group. The relapse rate was lower in the maintenance therapy continuation group than in the maintenance therapy discontinuation group (P = 0.035). Predictors of relapse after 3 years included cessation of maintenance therapy (hazard ratio [HR] = 3.76; 95 % confidence interval [CI] = 1.07-13.3, P = 0.040) and renal involvement (HR = 2.88; 95 % CI = 1.04-7.99, P = 0.042). The maintenance therapy continuation group showed a significantly higher prevalence of macrovascular complications, compared with the maintenance therapy discontinuation group (P = 0.005).
CONCLUSIONS: Cessation of steroid maintenance therapy and renal involvement were predictors of relapse after 3 years of maintenance therapy. However, the long-term use of steroids may increase the risk of macrovascular complications.
Participants will be asked to consume chicken that contains both omega3 (DHA/EPA) fatty acids and vitamin D (25(OH)D) for a 3week period. On the first day, you will be asked to spend around 9h in the HMRU, and will be fed a breakfast containing this chicken. A total of 5 blood samples will be collected over the 9h period. You will be asked to stay in the HMRU for this 9h study and will be fed breakfast, lunch and dinner. For the next 3w you will be asked to eat this chicken at lunch in the HMRU on the Cornell campus on weekdays (Monday-Friday). On weekends you will be given two packaged frozen chicken servings to eat at home (one serving per day). At 4 timepoints over the 3-week study, a blood draw will be collected to measure (25(OH)D) status and other nutrients (such as hemoglobin, hematocrit, and concentrations of omega-3 fatty acids). Each blood draw visit to the HMRU should last about 30 minutes. The time needed to complete this study in the HMRU is 10 hours over the 3w period.
Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
Writing Wrongs is an adaptation of expressive writing, a prolonged exposure practice targeting symptoms resulting from stressful life events. Writing Wrongs is specifically tailored to microaggressions experienced by minoritized students at predominantly White institutions. The intervention includes three 20-minute writing sessions occurring on three consecutive days. The Writing Wrongs writing activity asks participants to reflect on the facts and feelings associated with a microaggression they experienced.
1461812 Gypsum composition DENTSPLY INTERNATIONAL Inc 27 Feb 1974 [27 Feb 1973] 8854/74 Heading C1H [Also in Division C3] A modified gypsum composition comprises from 60-85 wt. per cent calcium sulphate hemihydrate which is curable by hydration, from 5- 20% by weight extender which is capable of holding in the composition after curing with water, a volume of chemically uncombined water at least equal to the volume of the extender, and from 3-15 wt. per cent of a waterswellable and water-dispersible compatible organic binder which is capable of enhancing the adherence of the added extender to the randomly-oriented crystals of the substantially completely hydrated gypsum in the composition after curing with water, whereby the cured composition has a fracture strength under compression of less than 500 p.s.i. The extender may be diatomaceous earth or perlite and may have a particle size of 5-44 microns. The binder may be a starch. A typical composition for making dentures comprises 60-85 wt. per cent plaster of Paris calcium sulphate hemihydrate, 5-15 wt. per cent cornstarch, 7-14 wt. per cent diatomaceous earth, 1-2 wt. per cent polyethylene oxide, 1 wt. per cent sodium chloride, 0À3 wt. per cent anionic surfactant (e.g. sodium octyl sulphosuccinate), 0À3 wt. per cent colourant and optionally 0À01 wt. per cent flavourant.
The present invention relates to the field of purification of algal extracts, methods for their preparation, the unique composition of such purified extracts and their applications. A particular, detailed example of the invention is provided relating to phycobiliprotein compositions and methods for their preparation and in particular to phycobiliprotein compositions with unique molecular markers. The phycobiliprotein compositions are characterized by unique protein components as assayed by 2-D gel electrophoresis. The present invention encompasses oral, topical, mucosal, nasal, ophthalmological and other formulations containing the phycobiliprotein compositions, either alone or in combination with other active agents. The unique compositions may be used for a large range of applications including to treat a variety of diseases and conditions, as a food and beverage ingredient, nutraceutical ingredient and food colorant, and in agriculture, animal nutrition, bioremediation and cell culture. The invention can be used for the purification of extracts 15 from a range of algae.
INTRODUCTION: Trigeminal neuralgia (TN), marked by chronic pain from neural damage, is closely associated with inflammation. The role of OTULIN, a key regulator in inflammation and autophagy, is not fully understood in TN. The regulatory mechanism of OTULIN, a key protein involved in modulating inflammatory responses and autophagy processes, remains incompletely elucidated, particularly in the context of TN and neuroinflammation.
METHODS: An infraorbital nerve ligation-induced rat model of TN was used. OTULIN's expression was modulated using adenovirus vectors and short hairpin RNA. The impact on pain and inflammatory responses was assessed via quantitative real-time polymerase chain reaction, western blot, immunofluorescence, and transcriptomic analysis.
RESULTS: Enhanced OTULIN expression significantly increased head withdrawal thresholds and reduced pain sensitivity and neuroinflammatory markers in the model. Conversely, silencing OTULIN exacerbated pain and inflammation. Transcriptomic data revealed OTULINs influence on both inflammatory and autophagy pathways, specifically in suppressing NLR family pyrin domain containing 3 (NLRP3) inflammasome and promoting autophagy. In vitro experiments demonstrated OTULIN's inhibition of inflammatory markers in microglia and neurons.
CONCLUSION: OTULIN is crucial in modulating TN, reducing neuropathic pain and neuroinflammation by activating the autophagy pathway and inhibiting the NLRP3 inflammasome.
Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
Social isolation is common in serious mental illness and has a profound negative impact on recovery. This study evaluates a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social behavior, and it also validates several new techniques for measuring social behavior. mSITE blends brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. The investigators will conduct an open trial of mSITE, evaluating whether the intervention leads to clinically significant changes in the frequency of social interactions. The investigators will also determine the dose of app plus remote coaching necessary to achieve this effect, by evaluating change at 12, 18, or 24 weeks. If found to be effective, a scalable intervention that reduces social isolation in serious mental illness would have significant personal, societal, and economic impact.
Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.